Biopharmaceuticals Pipeline Glycotope’s mature biopharmaceuticals pipeline Find out more
Biopharmaceuticals Services Glycotope’s unique development expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company, experienced leadership and Board
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
Gatipotuzumab
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
22. Dec
2017
Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies

Berlin, Germany, 22 December 2017 – Glycotope GmbH, a clinical-stage immuno-oncology company built on […]

30. Oct
2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany – (October 30, 2017) – Daiichi […]

See All News
Events
25-26 Jun
2018
6th Antibody Industrial Symposium
See All Events